AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15532340 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive HBP intervention
Number of subjects: 147
Study 15532340 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 147
Study 11555505 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-flow inspiratory muscle training (IMT) at 60 to 70% SIPmax, 30 min daily, 6 days a week for 6 months
Number of subjects: 20
Study 11555505 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 20
Study 11555505 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-flow inspiratory muscle training (IMT)
Number of subjects: 20
Study 9777109 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer group (CD-ROM study material)
Number of subjects: 72
Study 9777109 — intervention group
Group type: COMPARATOR
Intervention: Tutorial group
Number of subjects: 72
Study 9777109 — intervention group
Group type: COMPARATOR
Intervention: Control group (no study material)
Number of subjects: 72
Study 7829767 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 37
Study 7829767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 3245867 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol group (0.8 ml of 100% alcohol/kg body weight)
Number of subjects: 30
Study 3245867 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo group
Number of subjects: 30
Study 3245867 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 29370781 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX plus panitumumab
Number of subjects: 0
Study 29370781 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5FU) plus panitumumab
Number of subjects: 0
Study 29370781 — intervention group
Group type: EXPERIMENTAL
Intervention: G8 screening tool
Number of subjects: 0
Study 29370781 — intervention group
Group type: EXPERIMENTAL
Intervention: CRASH score
Number of subjects: 0
Study 26497692 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol group (0.4 g/kg)
Number of subjects: 75
Study 26497692 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 75
Study 26625004 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of paclitaxel and trastuzumab
Number of subjects: 227
Study 26625004 — intervention group
Group type: COMPARATOR
Intervention: 1 year of trastuzumab
Number of subjects: 227
Study 24024983 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.07% cetylpyridinium chloride (CPC) mouth rinse, used three times per day
Number of subjects: 67
Study 24024983 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouth rinse
Number of subjects: 67
Study 21440143 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation plus irbesartan
Number of subjects: 83
Study 21440143 — intervention group
Group type: COMPARATOR
Intervention: Ablation alone
Number of subjects: 83
Study 19636688 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic AF episodes
Number of subjects: 79
Study 19636688 — intervention group
Group type: EXPERIMENTAL
Intervention: Diurnal symptomatic AF
Number of subjects: 79
Study 19636688 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal symptomatic AF
Number of subjects: 79
Study 19636688 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity and positive predictive value
Number of subjects: 79
Study 16908795 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-automated feedback
Number of subjects: 192
Study 16908795 — intervention group
Group type: EXPERIMENTAL
Intervention: Human e-mail counseling
Number of subjects: 192
Study 16908795 — intervention group
Group type: COMPARATOR
Intervention: No counseling
Number of subjects: 192
Study 15598480 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 microg QID
Number of subjects: 70
Study 15598480 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg OD
Number of subjects: 70
Study 15598480 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg OD
Number of subjects: 70
Study 15598480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 11730396 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir, zidovudine, and lamivudine therapy
Number of subjects: 489
Study 7740330 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vinorelbine
Number of subjects: 0
Study 2225410 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg q.d.
Number of subjects: 620
Study 2225410 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg t.i.d.
Number of subjects: 620
Study 2225410 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg and dipyridamole 75 mg t.i.d.
Number of subjects: 620
Study 2225410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 620
Study 103467 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 mg or 450 mg daily of oral papaverine
Number of subjects: 11
Study 30209851 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle energy technique (MET)
Number of subjects: 80
Study 30209851 — intervention group
Group type: COMPARATOR
Intervention: Sham transcutaneous electrical nerve stimulation
Number of subjects: 80
Study 30209851 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 80
Study 28012023 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous methotrexate (MTX) administered via auto-injector into the abdomen (MTXAIab)
Number of subjects: 0
Study 28012023 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous methotrexate (MTX) administered via auto-injector into the thigh (MTXAIth)
Number of subjects: 0
Study 28012023 — intervention group
Group type: COMPARATOR
Intervention: Oral methotrexate (MTX)
Number of subjects: 0
Study 26303560 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care
Number of subjects: 110
Study 26303560 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 110
Study 26303560 — intervention group
Group type: COMPARATOR
Intervention: Institutional care
Number of subjects: 110
Study 24516645 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency (HF) training
Number of subjects: 21
Study 24516645 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate frequency (MF) training
Number of subjects: 21
Study 22943609 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-month treatment program of pharmacotherapy, standardized patient and provider education, and physician and patient counseling
Number of subjects: 63
Study 22943609 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 63
Study 19962845 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored education-coaching (TEC) intervention
Number of subjects: 148
Study 19962845 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 148
Study 17599629 — intervention group
Group type: EXPERIMENTAL
Intervention: epalrestat (50 mg/day p.o. ac, t.i.d.)
Number of subjects: 603
Study 17599629 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 603
Study 17599629 — intervention group
Group type: EXPERIMENTAL
Intervention: epalrestat
Number of subjects: 603
Study 16242556 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical embolectomy plus controlled reperfusion using a simplified perfusion system
Number of subjects: 15
Study 16242556 — intervention group
Group type: COMPARATOR
Intervention: Surgical embolectomy alone
Number of subjects: 15
Study 12121014 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin staplers
Number of subjects: 50
Study 12121014 — intervention group
Group type: COMPARATOR
Intervention: Monofilament sutures
Number of subjects: 50
Study 12121014 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 10450737 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic preperitoneal mesh (TAPP)
Number of subjects: 613
Study 10450737 — intervention group
Group type: COMPARATOR
Intervention: Open preperitoneal mesh
Number of subjects: 613
Study 10450737 — intervention group
Group type: COMPARATOR
Intervention: Conventional procedure
Number of subjects: 613
Study 8695558 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA A1, A33, B8, B47, B51, B53, B57, B62, DR3, DR12, DR13
Number of subjects: 128
Study 8695558 — intervention group
Group type: COMPARATOR
Intervention: HLA B12, B17, DR2
Number of subjects: 128
Study 8695558 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA antigens
Number of subjects: 128
Study 1804787 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 121
Study 1804787 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin clavulanate
Number of subjects: 121
Study 1804787 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 121
Study 6320400 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture on electrically detected points
Number of subjects: 30
Study 6320400 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture on 'placebo' points
Number of subjects: 30
Study 31925451 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based learning
Number of subjects: 88
Study 31925451 — intervention group
Group type: COMPARATOR
Intervention: Peer-assisted learning
Number of subjects: 88
Study 31925451 — intervention group
Group type: COMPARATOR
Intervention: Conventional teaching
Number of subjects: 88
Study 31925451 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (team-based, peer-assisted, conventional)
Number of subjects: 88
Study 31925451 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall course evaluation
Number of subjects: 88
Study 31759465 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years Teacher Classroom Management program
Number of subjects: 0
Study 31759465 — intervention group
Group type: COMPARATOR
Intervention: Wait-list comparison group
Number of subjects: 0
Study 29805066 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical vascularization pattern (90% of specimens) with ascending palatine and ascending pharyngeal artery
Number of subjects: 30
Study 29805066 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial variation (10% of specimens) with dependence on ascending pharyngeal artery alone
Number of subjects: 30
Study 29871088 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 75
Study 24746254 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic common bile duct exploration with primary closure (group A)
Number of subjects: 194
Study 24746254 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic common bile duct exploration with T-tube drainage (group B)
Number of subjects: 194
Study 24746254 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall postoperative complications (group A)
Number of subjects: 194
Study 21810288 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose oat β‐glucan (3·0 g β‐glucan; oats high ‐ OH)
Number of subjects: 87
Study 21810288 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oat β‐glucan (1·5 g β‐glucan; oats low ‐ OL)
Number of subjects: 87
Study 21810288 — intervention group
Group type: COMPARATOR
Intervention: Minimal β‐glucan (control)
Number of subjects: 87
Study 21810288 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose oat β‐glucan (3·0 g β‐glucan; oats high ‐ OH) in responders
Number of subjects: 87
Study 21810288 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oat β‐glucan (1·5 g β‐glucan; oats low ‐ OL) in responders
Number of subjects: 87
Study 21810288 — intervention group
Group type: COMPARATOR
Intervention: Minimal β‐glucan (control) in responders
Number of subjects: 87
Study 19602218 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0
Study 19602218 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 0
Study 17875827 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze 24/7 Anti-Wrinkle Cream
Number of subjects: 42
Study 17875827 — intervention group
Group type: EXPERIMENTAL
Intervention: LiftFusion Micro-Injected M-Tox Transdermal Face Lift
Number of subjects: 42
Study 17875827 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Nutraderm Therapeutic Lotion)
Number of subjects: 42
Study 15117834 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine challenge (DSMR)
Number of subjects: 29
Study 15117834 — intervention group
Group type: COMPARATOR
Intervention: Delayed enhancement imaging with Gd-DTPA (SCAR)
Number of subjects: 29
Study 11080606 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual visit with a physician
Number of subjects: 564
Study 11080606 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician visit plus a visit with a health educator
Number of subjects: 564
Study 11080606 — intervention group
Group type: EXPERIMENTAL
Intervention: Group visit of eight new members led by a physician and health educator
Number of subjects: 564
Study 11080606 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 564
Study 9846599 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg oral caffeine
Number of subjects: 30
Study 9846599 — intervention group
Group type: COMPARATOR
Intervention: Placebo (highly decaffeinated coffee)
Number of subjects: 30
Study 9501808 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective repair of asymptomatic AAA
Number of subjects: 0
Study 9501808 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for asymptomatic AAA
Number of subjects: 0
Study 9501808 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (trials ongoing)
Number of subjects: 0
Study 2623040 — intervention group
Group type: EXPERIMENTAL
Intervention: Active marijuana (1.3‐2.7% delta 9‐THC)
Number of subjects: 15
Study 2623040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 892957 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 5 mg, three times daily for 6 weeks
Number of subjects: 27
Study 892957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 30900025 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoculation with arbuscular mycorrhizal fungi (AMF) - Rhizophagus irregularis or Funneliformis mosseae or a mixture of both species
Number of subjects: 0
Study 30900025 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoculation with Pseudomonas fluorescens
Number of subjects: 0
Study 30900025 — intervention group
Group type: COMPARATOR
Intervention: Non-inoculated controls
Number of subjects: 0
Study 28087069 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg RG-101
Number of subjects: 32
Study 28087069 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg RG-101
Number of subjects: 32
Study 28087069 — intervention group
Group type: EXPERIMENTAL
Intervention: RG-101 (both dosages)
Number of subjects: 32
Study 28087069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 26076141 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotics group (PG)
Number of subjects: 672
Study 26076141 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 672
Study 26076141 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed group (BG)
Number of subjects: 672
Study 23816448 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychoeducation (21 sessions, weekly)
Number of subjects: 102
Study 23816448 — intervention group
Group type: COMPARATOR
Intervention: Standard psychiatric care (including standard pharmacological treatment)
Number of subjects: 102
Study 22117618 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual lifestyle counselling by a physician (IG) every six months for 18 months
Number of subjects: 213
Study 22117618 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual and interdisciplinary group-based program (IIG) over 16 weeks
Number of subjects: 213
Study 22117618 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined IG and IIG
Number of subjects: 213
Study 22117618 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 213
Study 19687781 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCC1 SNP rs4148382
Number of subjects: 2542
Study 19687781 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCC1 SNP rs212093
Number of subjects: 2542
Study 19687781 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCC1 SNP rs35621
Number of subjects: 2542
Study 16371411 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m² every 3 weeks (3W arm)
Number of subjects: 259
Study 16371411 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 36 mg/m² weekly (1W arm)
Number of subjects: 259
Study 15482167 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymalfasin (Talpha1) 1.6 mg twice-weekly for 6 months
Number of subjects: 0
Study 15482167 — intervention group
Group type: COMPARATOR
Intervention: Thymalfasin (Talpha1)
Number of subjects: 0
Study 15482167 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymalfasin (Talpha1) and interferon combination therapy
Number of subjects: 0
Study 10906101 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C application during DCR surgery (0.2 mg/ml for 30 minutes)
Number of subjects: 88
Study 10906101 — intervention group
Group type: COMPARATOR
Intervention: Conventional DCR surgery
Number of subjects: 88
Study 10906101 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C application during DCR surgery
Number of subjects: 88
Study 9289023 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented enteral group (group 1)
Number of subjects: 30
Study 9289023 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral standard group (group 2)
Number of subjects: 30
Study 9289023 — intervention group
Group type: COMPARATOR
Intervention: Parenteral group (group 3)
Number of subjects: 30
Study 8513961 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg RU486 (single dose)
Number of subjects: 60
Study 8513961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2426419 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine 0.4 mg/kg/cycle
Number of subjects: 214
Study 2426419 — intervention group
Group type: COMPARATOR
Intervention: Vinblastine 0.3 mg/kg/cycle
Number of subjects: 214
Study 29601488 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit smoothie
Number of subjects: 47
Study 29601488 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh fruit equivalent of the smoothie
Number of subjects: 47
Study 29601488 — intervention group
Group type: EXPERIMENTAL
Intervention: Blackcurrant squash
Number of subjects: 47
Study 29601488 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 47
Study 29601488 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 47
Study 29601488 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-containing preloads (fruit smoothie, fresh fruit, blackcurrant squash, milk)
Number of subjects: 47
Study 27588540 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported substance use (alcohol and tobacco) in 12th grade
Number of subjects: 1044
Study 27588540 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligibility for free or reduced-price lunch in 6th grade
Number of subjects: 1044
Study 27588540 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use in 6th grade
Number of subjects: 1044
Study 27588540 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette use in 12th grade
Number of subjects: 1044
Study 27588540 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use in 12th grade
Number of subjects: 1044
Study 23920211 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational support group (viewed 2 consecutive polysomnograms)
Number of subjects: 206
Study 23920211 — intervention group
Group type: COMPARATOR
Intervention: Standard support group
Number of subjects: 206
Study 23920211 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational support group
Number of subjects: 206
Study 23272529 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptogens (multiple dose administration, twice daily) plus standard prevention protocol (lifestyle counseling)
Number of subjects: 40
Study 23272529 — intervention group
Group type: COMPARATOR
Intervention: Standard prevention protocol (lifestyle counseling) only
Number of subjects: 40
Study 20660805 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance improvement intervention
Number of subjects: 34810
Study 18488880 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tazarotene
Number of subjects: 0
Study 18488880 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical retinoids (including tretinoin and isotretinoin)
Number of subjects: 0
Study 16133397 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 55
Study 16133397 — intervention group
Group type: COMPARATOR
Intervention: Bone Scintigraphy
Number of subjects: 55
Study 12236311 — intervention group
Group type: COMPARATOR
Intervention: K file using step‐back technique without coronal flaring (control; group 1)
Number of subjects: 30
Study 12236311 — intervention group
Group type: EXPERIMENTAL
Intervention: K file using step‐back technique after coronal flaring (group 2)
Number of subjects: 30
Study 12236311 — intervention group
Group type: EXPERIMENTAL
Intervention: LightSpeed instrumentation (group 3)
Number of subjects: 30
Study 10441602 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of immunotherapy
Number of subjects: 0
Study 10441602 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of immunotherapy
Number of subjects: 0
Study 10441602 — intervention group
Group type: COMPARATOR
Intervention: Control group (no immunotherapy)
Number of subjects: 0
Study 10441602 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (continuation and discontinuation)
Number of subjects: 0
Study 7801862 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem (bolus dose followed by continuous infusion at 5, 10, and 15 mg/hour)
Number of subjects: 84
Study 7801862 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of diltiazem at 5 mg/hour
Number of subjects: 84
Study 7801862 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of diltiazem at 10 mg/hour
Number of subjects: 84
Study 7801862 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of diltiazem at 15 mg/hour
Number of subjects: 84
Study 7801862 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of diltiazem (all doses)
Number of subjects: 84